Latest Compliance News

Group 6 Metals Limited has reported a striking turnaround with a $25.6 million revenue haul and a return to profit, driven by soaring tungsten prices and operational gains at its Dolphin Tungsten Project. The company is now gearing up for underground mining to sustain growth.

Pearl Gull Iron Limited’s shares have been suspended from ASX trading following the sale of its main asset, the Cockatoo Island Project, as the company works to meet compliance requirements.

Pearl Gull Iron Limited has been suspended from ASX trading after failing to meet operational requirements, raising questions about its future on the exchange.

Nimy Resources has addressed a recent spike in its share price and trading volume, attributing the movement to its Managing Director's U.S. trade mission and the release of a commissioned research article.

Beetaloo Energy has responded to ASX concerns over a delayed disclosure of a director's change in interest, attributing it to an administrative oversight and pledging enhanced compliance measures.

Deep Yellow Limited has firmly denied recent media speculation about a capital raising, reaffirming its compliance with ASX continuous disclosure rules.

Paterson Resources has responded to an ASX price query following a notable rise in its share price and trading volume, confirming no undisclosed information is driving the recent market activity.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Magellan Financial Group has applied for quotation of over 15 million new shares following a recent transaction, alongside announcing a $20 million Share Purchase Plan targeting further capital raising.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Bapcor Limited has initiated a fully underwritten $200 million equity raising at $0.60 per share, aiming to reduce debt and support a strategic turnaround under new leadership. The retail entitlement offer opened on 5 March and closes on 19 March 2026.

Identitii Limited has closed its recent rights issue, raising $379,336 before costs but falling short by $2.5 million after the termination of its underwriting agreement. The company plans to issue new shares and place the remaining shortfall to fund growth initiatives for its BNDRY platform.